NEAUTUS (02206.HK): grey market price at HK$49.50, up 23.13% from HK$40.20 offer price, listing on 11 November
NewTimeSpace News: On 10 November 2026, grey market trading in Sichuan Neautus Traditional Chinese Medicine Co., Ltd. (02206.HK) took place in the afternoon. As at 6:08 p.m., the grey market price stood at HK$49.50, up HK$9.30 or 23.13% from the offer price of HK$40.20. The Company's shares will commence trading on the Main Board of the Stock Exchange on 11 November 2026, with a nominal value of RMB1.00 per share.
On the offering, the offer price range was HK$40.20 to HK$50.55 per share and the final price was fixed at the lower limit of HK$40.20. The global offering comprised 6.5173 million H shares, of which 651,800 H shares were under the Hong Kong public offer (10%, or 13,035 board lots) and 5.8656 million H shares under the international offering (90%), with a board lot of 50 shares and an entrance fee of approximately HK$2,552.99 based on the upper limit. Market sources indicated that the public offer was about 2,192 times oversubscribed, attracting around 59,000 applicants. The Company did not introduce cornerstone investors and has not granted an over-allotment option. Based on the mid-point of the offer price range, net proceeds were approximately HK$230 million.
Founded in Chengdu in 2001, the Company was China's first GMP-certified decoction pieces factory and focuses on toxic and ordinary decoction pieces, offering more than 770 types and 4,900 specifications and serving over 1,000 hospitals and medical institutions, with a sales network covering more than 30 provinces in the mainland as well as Hong Kong, Taiwan and Southeast Asia. By 2025 revenue from decoction pieces, it ranked second nationwide and first among non-state-owned enterprises. The proceeds are intended for expanding production capacity and upgrading its digital intelligent production system, sales and marketing activities, consumer-facing business, establishing overseas sales channels in Vietnam and Malaysia, and strategic investments and potential acquisitions.
